Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium

Modern Pathology

Volumn 23, Issue 11, 2010, Pages 1458-1466

  Sato, Ayuko ^a   Torii, Ikuko ^a   Okamura, Yoshihiro ^a   Yamamoto, Tadashi ^a   Nishigami, Takashi ^a   Kataoka, Tatsuki R ^a   Song, Misa ^a   Hasegawa, Seiki ^a   Nakano, Takashi ^a   Kamei, Toshiaki ^b   Tsujimura, Tohru ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b Yamaguchi Grand Medical Center   (Japan)

Author keywords

CD146; cytology; immunocytochemistry; malignant mesothelioma; pleural effusion; reactive mesothelium

Indexed keywords

BIOLOGICAL MARKER; CD146 ANTIBODY; CD146 ANTIGEN; LYMPHOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CELL INTERACTION; CELL MEMBRANE; CLONE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; HEART FAILURE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MALIGNANT MESOTHELIOMA; MESOTHELIUM; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PLEURISY; PNEUMONIA; PRIORITY JOURNAL; REACTIVE MESOTHELIUM; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER;

EID: 78049452833     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.134     Document Type: Article

References (30)

1. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005;353:1591-1603.
2. Tsao AS, Wistuba I, Roth JA, et al. Malignant pleural mesothelioma. J Clin Oncol 2009;27:2081-2090.
3. Robinson BWS, Chahinian AP, (eds) Mesothelioma. Martin Dunitz: London, 2002, pp 366.
4. Whitaker D. The cytology of malignant mesothelioma. Cytopathology 2000;11:139-151.
5. Stevens MW, Leong AS, Fazzalari NL, et al. Cyto-pathology of malignant mesothelioma: a stepwise logistic regression analysis. Diagn Cytopathol 1992;8: 333-341.
6. Churg A, Cagle PT, Roggli VL. Cytology of the serosal surfaces. In: Silverberg SG, Sobin LH (eds). AFIP Atlas of Tumor Pathology: Tumors of the Serosal Membranes. 4th series, fascicle 3. American Registry of Pathology in collaboration with the Armed Forces Institute of Pathology: Washington, DC, 2006, pp 11-31.
7. Cakir E, Demirag F, Aydin M, et al. Cytopathologic differential diagnosis of malignant mesothelioma, adenocarcinoma and reactive mesothelial cells: a logistic regression analysis. Diagn Cytopathol 2009; 37:4-10.
8. Fetsch PA, Abati A. Immunocytochemistry in effusion cytology: a contemporary review. Cancer 2001;93: 293-308.
9. Pu RT, Pang Y, Michael CW. Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelio-ma in effusions. Diagn Cytopathol 2008;36:20-25.
10. Wolanski KD, Whitaker D, Shilkin KB, et al. The use of epithelial membrane antigen and silver-stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive me-sothelioses. Cancer 1998;82:583-590.
11. Hurlimann J. Desmin and neural marker expression in mesothelial cells and mesotheliomas. Hum Pathol 1994;25:753-757.
12. Kato Y, Tsuta K, Seki K, et al. Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol 2007;20:215-220.
13. Ramael M, Lemmens G, Eerdekens C, et al. Immunor-eactivity for p53 protein in malignant mesothelioma and non-neoplastic mesothelium. J Pathol 1992;168: 371-375.
14. Cury PM, Butcher DN, Corrin B, et al. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperpla-sia and reactive pleural fibrosis. J Pathol 1999;189: 251-257.
15. King J, Thatcher N, Pickering C, et al. Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports. Histopathology 2006;49:561-568.
16. Shen J, Pinkus GS, Deshpande V, et al. Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids. Am J Clin Pathol 2009;131:516-523.
17. Davidson B, Nielsen S, Christensen J, et al. The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothe-lial and epithelial cells. Am J Surg Pathol 2001;25: 1405-1412.
18. Saad RS, Cho P, Liu YL, et al. The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelio-ma: a comparative study. Diagn Cytopathol 2005;32: 156-159.
19. Edelman GM, Crossin KL. Cell adhesion molecules: implications for a molecular histology. Annu Rev Biochem 1991;60:155-190.
20. Albelda SM. Role of integrins and other cell adhesion molecules in tumor progression and metastasis. Lab Invest 1993;68:4-17.
21. Lehmann JM, Riethmüller G, Johnson JP. MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad Sci USA 1989;86:9891-9895.
22. Shih IM, Elder DE, Speicher D, et al. Isolation and functional characterization of the A32 melanoma-associated antigen. Cancer Res 1994;54:2514-2520.
23. Wu GJ, Varma VA, Wu MW, et al. Expression of a human cell adhesion molecule, MUC18, in prostate cancer cell lines and tissues. Prostate 2001;48: 305-315.
24. Wu GJ, Wu MW, Wang SW, et al. Isolation and characterization of the major form of human MUC18 cDNA gene and correlation of MUC18 over-expression in prostate cancer cell lines and tissues with malignant progression. Gene 2001;279:17-31.
25. Aldovini D, Demichelis F, Doglioni C, et al. M-CAM expression as marker of poor prognosis in epithelial ovarian cancer. Int J Cancer 2006;119:1920-1926.
26. Kimura N, Dota K, Araya Y, et al. Scoring system for differential diagnosis of malignant mesothelioma and reactive mesothelial cells on cytology specimens. Diagn Cytopathol 2009;37:885-890.
27. Bidlingmaier S, He J, Wang Y, et al. Identification of MCAM/CD146 as the target antigen of a human monoclonal antibody that recognizes both epithelioid and sarcomatoid types of mesothelioma. Cancer Res 2009;69:1570-1577.
28. Kristiansen G, Yu Y, Schlüns K, et al. Expression of the cell adhesion molecule CD146/MCAM in non-small cell lung cancer. Anal Cell Pathol 2003;25:77-81.
29. Shih LM, Hsu MY, Palazzo JP, et al. The cell-cell adhesion receptor Mel-CAM acts as a tumor suppressor in breast carcinoma. Am J Pathol 1997;151:745-751.
30. Mills L, Tellez C, Huang S, et al. Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. Cancer Res 2002;62:5106-5114.